Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Hyperactivity, impulsiveness, and distractibility are common problems in children with autism spectrum disorder (ASD). Extended-release guanfacine is approved for children with attention deficit hyperactivity disorder but not well studied in ASD. METHOD: In a multisite, randomized clinical trial, extended-release guanfacine was compared with placebo in children with ASD accompanied by hyperactivity, impulsiveness, and distractibility. RESULTS: Sixty-two subjects (boys, N=53; girls, N=9; mean age=8.5 years [SD=2.25]) were randomly assigned to guanfacine (N=30) or placebo (N=32) for 8 weeks. The guanfacine group showed a 43.6% decline in scores on the Aberrant Behavior Checklist-hyperactivity subscale (least squares mean from 34.2 to 19.3) compared with a 13.2% decrease in the placebo group (least squares mean from 34.2 to 29.7; effect size=1.67). The rate of positive response (much improved or very much improved on the Clinical Global Impression-Improvement scale) was 50% (15 of 30) for guanfacine compared with 9.4% (3 of 32) for placebo. A brief cognitive battery tapping working memory and motor planning showed no group differences before or after 8 weeks of treatment. The modal dose of guanfacine at week 8 was 3 mg/day (range: 1-4 mg/day), and the modal dose was 3 mg/day (range: 2-4 mg/day) for placebo. Four guanfacine-treated subjects (13.3%) and four placebo subjects (12.5%) exited the study before week 8. The most common adverse events included drowsiness, fatigue, and decreased appetite. There were no significant changes on ECG in either group. For subjects in the guanfacine group, blood pressure declined in the first 4 weeks, with return nearly to baseline by endpoint (week 8). Pulse rate showed a similar pattern but remained lower than baseline at endpoint. CONCLUSIONS: Extended-release guanfacine appears to be safe and effective for reducing hyperactivity, impulsiveness, and distractibility in children with ASD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A large trial of balovaptan, a vasopressin AVPR1A antagonist in adults with ASD showed negative results on its primary outcome ( a general rating of ASD symptoms), with suggestive results on a key secondary parent report measure of adaptive behaviour, including social and communication behaviour 212 .”
From Autism spectrum disorder (2020) · cites this paper as [212]
In the citing paper
“The results of this trial indicated that guanfacine ER is safe and efficacious for the short-term treatment of ADHD symptoms in children and adolescents with ASD [83].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
In the citing paper
“The guanfacine group had a 50% positive response rate on the Clinical Global Impressions-Improvement (CGI-I) scale compared to 9.4% for placebo.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
In the citing paper
“ABC-Hyperactivity subscale scores fell by 43.6% in the active treatment group and 13.2% in the placebo group.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
In the citing paper
“Drowsiness, fatigue, emotional/tearful presentation, dry mouth, and irritability were the most common side effects in the active treatment arm.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [83]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318179964f · Cited by 3,399
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Global Prevalence of Autism and Other Pervasive Developmental Disorders
Elsabbagh, M., Divan, G., Koh, Y., Kim, Y. S., Kauchali, S., Marcín, C., Montiel‐Nava, C., Patel, V., Paula, C. S., Wang, C., et al. (2012) · Autism Research · doi:10.1002/aur.239 · Cited by 2,636
Mullen Scales of Early Learning
Bradley-Johnson, S. (1997) · Psychology in the Schools · doi:10.1002/(sici)1520-6807(199710)34:4<379::aid-pits14>3.0.co;2-e · Cited by 2,325
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Thompson Coon, J. (2002) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.2002.tb05480.x · Cited by 1,744
Stanford-Binet Intelligence Scale
(2012) · SpringerReference · doi:10.1007/springerreference_70151 · Cited by 1,664
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Self-citation
Research works printed but not linked: 7
- American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders-Text Revised
- Sparrow SS, 2005, Vineland-II Adaptive Behavior Scales
- Aman MG, 1985, Am J Ment Defic, 89, 485
- Elliott C, 2007, Differential Ability Scales-II (DAS-II)
- Korkman M, 2007, NEPSYII: Administration Manual
- Board AW, 1988, Clin Ther, 10, 761
- 10.1093/biostatistics/kxh001 · DOI · Paper page
Cited by
Lord, C., Elsabbagh, M., Baird, G., & Veenstra-Vanderweele, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31129-2 · Cited by 2,819
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Autism Spectrum Disorder: A Review
Hirota, T., & King, B. H. (2023) · JAMA · doi:10.1001/jama.2022.23661 · Cited by 957
Self-citationThe Lancet Commission on the future of care and clinical research in autism
Lord, C., Charman, T., Havdahl, A., Carbone, P., Anagnostou, E., Boyd, B., Carr, T., de Vries, P. J., Dissanayake, C., Divan, G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01541-5 · Cited by 924
Self-citationAutism Spectrum Disorder: Classification, diagnosis and therapy
Sharma, S. R., Gonda, X., & Tarazi, F. I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.007 · Cited by 673
Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342
Self-citationClinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD)
Genovese, A., & Butler, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134726 · Cited by 268
An update on the comorbidity of ADHD and ASD: a focus on clinical management
Antshel, K. M., Zhang-James, Y., Wagner, K. E., Ledesma, A., & Faraone, S. V. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1146591 · Cited by 262
An update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
Fuentes, J., Hervás, A., Howlin, P., & Party), (. A. W. (2021) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-020-01587-4 · Cited by 183
Treatment of Autism Spectrum Disorder in Children and Adolescents
DeFilippis, M., & Wagner, K. D. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4346 · Cited by 177
An update on pharmacotherapy of autism spectrum disorder in children and adolescents
Goel, R., Hong, J. S., Findling, R. L., & Ji, N. Y. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1458706 · Cited by 176
Barbaresi, W. J., Campbell, L., Diekroger, E. A., Froehlich, T. E., Liu, Y. H., O'Malley, E., Pelham, W. E., Power, T. J., Zinner, S. H., & Chan, E. (2020) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000000770 · Cited by 153
An exploration of concomitant psychiatric disorders in children with autism spectrum disorder
Lecavalier, L., McCracken, C. E., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Smith, T., Johnson, C., King, B., Handen, B., et al. (2019) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2018.10.012 · Cited by 127
Self-citationPersico, A. M., Ricciardello, A., Lamberti, M., Turriziani, L., Cucinotta, F., Brogna, C., Vitiello, B., & Arango, C. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110326 · Cited by 155
Rodrigues, R., Lai, M., Beswick, A., Gorman, D. A., Anagnostou, E., Szatmari, P., Anderson, K. K., & Ameis, S. H. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13305 · Cited by 98
Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions
McCracken, J. T., Anagnostou, E. A., Arango, C., Dawson, G., Farchione, T. R., Mantua, V., McPartland, J. C., Murphy, D., Pandina, G., & Veenstra-VanderWeele, J. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.05.010 · Cited by 97
Self-citationFrye, R. E., & Rossignol, D. A. (2016) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s38337 · Cited by 96
Politte, L. C., Scahill, L., Figueroa, J., McCracken, J. T., King, B., & McDougle, C. J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0039-3 · Cited by 90
“In our report of primary findings for the GEXR study [10], we reported no statistically significant differences in irritability with treatment between the GEXR and placebo groups, as assessed by the ABC-irritability subscale (ES= 0.”
BackgroundMethodInfluentialSelf-citationSleep in autism: A biomolecular approach to aetiology and treatment
Ballester, P., Richdale, A. L., Baker, E. K., & Peiró, A. M. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101357 · Cited by 90
Pharmacotherapy for mental health problems in people with intellectual disability
Ji, N. Y., & Findling, R. L. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000233 · Cited by 88
Pharmacotherapeutic management of sleep disorders in children with neurodevelopmental disorders
Bruni, O., Angriman, M., Melegari, M. G., & Ferri, R. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1674283 · Cited by 84
A Personalized Multidisciplinary Approach to Evaluating and Treating Autism Spectrum Disorder
Frye, R. E. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030464 · Cited by 81
Clinical trials in autism spectrum disorder: evidence, challenges and future directions
Anagnostou, E. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000542 · Cited by 72
Murphy, T. K., Fernandez, T. V., Coffey, B. J., Rahman, O., Gavaletz, A., Hanks, C. E., Tillberg, C. S., Ibanez-Gomez, L., Sukhodolsky, D. G., Katsovich, L., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0024 · Cited by 80
Self-citationSystematic review and guide to management of core and psychiatric symptoms in youth with autism
Ameis, S. H., Kassee, C., Corbett‐Dick, P., Cole, L., Dadhwal, S., Lai, M. ‐., Veenstra‐VanderWeele, J., & Correll, C. U. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12918 · Cited by 64
Yerys, B. E., Bertollo, J. R., Kenworthy, L. E., Dawson, G., Marco, E. J., Schultz, R. T., & Sikich, L. (2018) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-018-3856-7 · Cited by 72
Iffland, M., Livingstone, N., Jorgensen, M. L., Hazell, P., & Gillies, D. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011769.pub2 · Cited by 71
Placebo‐like response in absence of treatment in children with Autism
Jones, R. M., Carberry, C., Hamo, A., & Lord, C. (2017) · Autism Research · doi:10.1002/aur.1798 · Cited by 65
CE: From the CDC: Understanding Autism Spectrum Disorder
Christensen, D., & Zubler, J. M. (2020) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000718628.09065.1b · Cited by 71
Lamy, M., & Erickson, C. A. (2018) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2018.08.015 · Cited by 69
Predictors of Caregiver Strain for Parents of Children with Autism Spectrum Disorder
Bradshaw, J. L., Gillespie, S. E., McCracken, C., King, B. H., McCracken, J. T., Johnson, C. R., Lecavalier, L., Smith, T. H., Swiezy, N. B., Bearss, K. E., et al. (2020) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-020-04625-x · Cited by 68
Self-citationStepanova, E. A., Dowling, S., Phelps, M., & Findling, R. L. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.4/rfindling · Cited by 66
Yerys, B. E., Tunç, B., Satterthwaite, T. D., Antezana, L., Mosner, M. G., Bertollo, J. R., Guy, L., Schultz, R. T., & Herrington, J. D. (2019) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.12.012 · Cited by 63
Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder
Frye, R. E., Rossignol, D. A., Scahill, L. D., McDougle, C. J., Huberman, H. S., & Quadros, E. V. (2020) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2020.100835 · Cited by 63
Self-citationThe psychopharmacology of autism spectrum disorder and Rett syndrome
Persico, A. M., Ricciardello, A., & Cucinotta, F. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00024-1 · Cited by 60
Comorbid Behavioral Problems and Psychiatric Disorders in Autism Spectrum Disorders
Belardinelli, C., & Raza, M. (2016) · Journal of Childhood & Developmental Disorders · doi:10.4172/2472-1786.100019 · Cited by 38
Johnson, C. R., Barto, L., Worley, S., Rothstein, R., & Alder, M. L. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.08.033 · Cited by 58
Understanding, Assessing, and Intervening with Emotion Dysregulation in Autism Spectrum Disorder
Keluskar, J. L., Reicher, D., Gorecki, A., Mazefsky, C. A., & Crowell, J. A. (2021) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2020.10.013 · Cited by 57
Risperidone or Aripiprazole Can Resolve Autism Core Signs and Symptoms in Young Children: Case Study
Alsayouf, H. A., Talo, H., Biddappa, M. L., & Reyes, E. D. L. (2021) · Children · doi:10.3390/children8050318 · Cited by 57
Lecavalier, L., Smith, T., Johnson, C., Bearss, K., Swiezy, N., Aman, M. G., Sukhodolsky, D. G., Deng, Y., Dziura, J., & Scahill, L. (2017) · Journal of Abnormal Child Psychology · doi:10.1007/s10802-016-0233-x · Cited by 44
Self-citationPharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials
Hellings, J. A. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i6.262 · Cited by 52
Manter, M. A., Birtwell, K. B., Bath, J., Friedman, N. D. B., Keary, C. J., Neumeyer, A. M., Palumbo, M. L., Thom, R. P., Stonestreet, E., Brooks, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-024-03814-0 · Cited by 51
“Sixty-two subjects, ages 5–14 years, diagnosed with autistic disorder, Asperger’s disorder, or PDD-NOS, participated in an 8-week RCT of guanfacine ER to target symptoms of hyperactivity, impulsiveness, and distract-ibility [83].”
Self-citationBennett (2023) · doi:10.1097/yco.0000000000000775 · Cited by 51
Bertelli, M. O., Azeem, M. W., Underwood, L., Scattoni, M. L., Persico, A. M., Ricciardello, A., Sappok, T., Bergmann, T. J., Keller, R., Bianco, A., et al. (2022) · Springer eBooks · doi:10.1007/978-3-319-95720-3_16 · Cited by 48
Maniram, J., Karrim, S. B., Oosthuizen, F., & Wiafe, E. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s371013 · Cited by 44
An integrated transcriptomic analysis of autism spectrum disorder
He, Y., Zhou, Y., Ma, W., & Wang, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-48160-x · Cited by 44
Breaux, R., Baweja, R. K., Eadeh, H., Shroff, D. M., Cash, A. R., Swanson, C. S., Knehans, A. C., & Waxmonsky, J. G. (2022) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.05.012 · Cited by 43
Lamy, M., Pedapati, E. V., Dominick, K. C., Wink, L. K., & Erickson, C. A. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00408-0 · Cited by 43
Tsujii, N., Usami, M., Naya, N., Tsuji, T., Mishima, H., Horie, J., Fujiwara, M., & Iida, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00249-0 · Cited by 42
Holdman, R., Vigil, D., Robinson, K. J., Shah, P., & Contreras, A. E. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0154 · Cited by 39
Jones, R. M., Skwerer, D. P., Pawar, R., Hamo, A., Carberry, C., Ajodan, E. L., Caulley, D., Silverman, M. R., McAdoo, S., Meyer, S., et al. (2019) · Autism Research · doi:10.1002/aur.2071 · Cited by 39
Attention Deficit Hyperactivity Disorder Symptoms in Young Children with Autism Spectrum Disorder
Hong, J. S., Singh, V., & Kalb, L. G. (2020) · Autism Research · doi:10.1002/aur.2414 · Cited by 38
Popow, C., Ohmann, S., & Plener, P. L. (2021) · Neuropsychiatrie · doi:10.1007/s40211-021-00395-9 · Cited by 36
Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity Disorder
Wigal, S. B., Chappell, P. B., Palumbo, D. R., Lubaczewski, S. L., Ramaker, S., & Abbas, R. (2020) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0116 · Cited by 35
Koevoet, D., Deschamps, P. K. H., & Kenemans, J. L. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1078586 · Cited by 33
Joshi, G., Wilens, T. E., Firmin, E. S., Hoskova, B., & Biederman, J. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120972336 · Cited by 32
Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder
Henneberry, E. A., Lamy, M., Dominick, K. C., & Erickson, C. A. (2021) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05237-9 · Cited by 32
Teo, S.-H. J., Poh, X. W. W., Lee, T.-S. W., Guan, C., Cheung, Y. B., Fung, D. S. S., Zhang, H., Chin, Z. Y., Wang, C. C., Sung, M., et al. (2021) · Research in Autism · doi:10.1016/j.rasd.2021.101882 · Cited by 29
Methylphenidate in Autism Spectrum Disorder: A Long-Term Follow Up Naturalistic Study
Ventura, P., de Giambattista, C., Spagnoletta, L., Trerotoli, P., Cavone, M., Gioia, A. D., & Margari, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082566 · Cited by 28
Ota, T., Yamamuro, K., Okazaki, K., & Kishimoto, T. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s221126 · Cited by 28
Thom, R. P., Pereira, J. A., Sipsock, D., & McDougle, C. J. (2021) · Current Psychiatry Reports · doi:10.1007/s11920-021-01292-2 · Cited by 28
Self-citationManagement of Emotion Dysregulation and Outbursts in Children and Adolescents
Sorter, M. T., Chua, J. D., Lamy, M., Barzman, D. H., Ryes, L. A., & Shekhtman, J. A. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01325-4 · Cited by 26
Albertini, M. L., Spoto, G., Ceraolo, G., Fichera, M. F., Consoli, C., Nicotera, A. G., & Rosa, G. D. (2025) · Brain Sciences · doi:10.3390/brainsci15090983 · Cited by 25
Scahill, L. D., Bearss, K. E., Sarhangian, R., McDougle, C. J., Arnold, L. E., Aman, M. G., McCracken, J. T., Tierney, E., Gillespie, S. E., Postorino, V., et al. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0107 · Cited by 25
Self-citationVo, L. C., Snyder, C. S., McCracken, C. M., McDougle, C. J., McCracken, J. T., Aman, M. G., Tierney, E., Arnold, L. E., Levi, D. S., Kelleman, M. S., et al. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0090 · Cited by 24
Self-citationADHD in children and youth: Part 3—Assessment and treatment with comorbid ASD, ID, or prematurity
Clark, B., & Bélanger, S. A. (2018) · Paediatrics & Child Health · doi:10.1093/pch/pxy111 · Cited by 24
Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents
Santosh, P., & Singh, J. (2016) · BJPsych Advances · doi:10.1192/apt.bp.115.014597 · Cited by 24
New Assessments and Treatments in ASD
Choueiri, R., & Zimmerman, A. W. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0443-8 · Cited by 24
Therapy and Psychotropic Medication Use in Young Children With Autism Spectrum Disorder
Ziskind, D., Bennett, A. E., Jawad, A. F., & Blum, N. J. (2020) · PEDIATRICS · doi:10.1542/peds.2019-1895m · Cited by 24
Hollway, J. A., Mendoza-Burcham, M., Andridge, R., Aman, M. G., Handen, B. L., Arnold, L. E., Lecavalier, L., Williams, C. E., Silverman, L. B., & Smith, T. H. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0085 · Cited by 23
Cannabinoid treatment for the symptoms of autism spectrum disorder
Aran, A. A., & Cayam-Rand, D. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2306290 · Cited by 21
Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism
Tumuluru, R. V., Corbett-Dick, P., Aman, M. G., Smith, T. H., Arnold, L. E., Pan, X. J., Buchan-Page, K. A., Brown, N. V., Ryan, M. M., Hyman, S. L., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0187 · Cited by 21
Singh, D., Wakimoto, Y., Filangieri, C. M., Pinkhasov, A., & Angulo, M. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0102 · Cited by 21
Current and emerging treatment options for Angelman syndrome
Keary, C. J., & McDougle, C. J. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2245568 · Cited by 20
Self-citationAvailable Treatments for Autism Spectrum Disorder: From Old Strategies to New Options
Dell’Osso, L., Bonelli, C., Giovannoni, F., Poli, F., Anastasio, L., Cerofolini, G., Nardi, B., Cremone, I. M., Pini, S., & Carpita, B. (2025) · Pharmaceuticals · doi:10.3390/ph18030324 · Cited by 20
An Introduction to the Psychopharmacology of Children and Adolescents With Autism Spectrum Disorder
Earle, J. F. (2016) · Journal of Child and Adolescent Psychiatric Nursing · doi:10.1111/jcap.12144 · Cited by 20
Childress, A. C., Hoo-Cardiel, A., & Lang, P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1706480 · Cited by 20
Rol de la terapia farmacológica en los trastornos del espectro autista
Reyes, E., & Pizarro, L. (2022) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2022.07.002 · Cited by 20
Mevers, J. L., Call, N. A., Gerencser, K. R., Scheithauer, M. C., Miller, S. J., Muething, C., Hewett, S., McCracken, C., Scahill, L. D., & McElhanon, B. O. (2019) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-019-04305-5 · Cited by 19
Self-citationAlsayouf, H. A., Talo, H., Biddappa, M. L., Qasaymeh, M. M., Qasem, S. A., & Reyes, E. D. L. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s277294 · Cited by 19
Gupta, N., & Gupta, M. (2023) · CNS Spectrums · doi:10.1017/s1092852923002389 · Cited by 18
Wong, C. M., Aljunied, M., Chan, D. K. L., Cheong, J. M. Y., Chew, B., Chin, C. H., Choo, S. H. T., Chua, A. H. L., Foo, M. T. S., Goh, T. J., et al. (2024) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2023307 · Cited by 17
Pharmacological treatments in autism spectrum disorder: a narrative review
Davico, C., Secci, I., Vendrametto, V., & Vitiello, B. (2023) · Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology · Cited by 17
ADHD (aktiivisuuden ja tarkkaavuuden häiriö) : Käypä hoito -suositus
SUOMALAISEN LÄÄKÄRISEURAN DUODECIMIN, S. L. Y. (2017) · Helda - University of Helsinki Institutional Repository · Cited by 17
Sclabassi, E., Peret, S., Qian, C., & Gao, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13123025 · Cited by 15
Domenico, C. D., Alito, A., Leonardi, G., Pironti, E., Cara, M. D., Piccolo, A., Settimo, C., Quartarone, A., Gagliano, A., & Cucinotta, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14114000 · Cited by 15
Gender Differences in Treatment-Seeking Youth with Autism Spectrum Disorder
Cariveau, T., McCracken, C., Bradshaw, J. L., Postorino, V., Shillingsburg, M. A., McDougle, C. J., Aman, M. G., McCracken, J. T., Tierney, E., Johnson, C. R., et al. (2021) · Journal of Child and Family Studies · doi:10.1007/s10826-021-01905-7 · Cited by 15
Self-citationBreaux, R., Dunn, N. C., Swanson, C. S., Larkin, E., Waxmonsky, J. G., & Baweja, R. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.794044 · Cited by 15
Lilja, M. M., Sandblom, E., Lichtenstein, P., Serlachius, E., Hellner, C., Bhagia, J., & Halldner, L. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09424-2 · Cited by 14
Miyoshi, T., Mizushima, C., Noborio, Y., Kimoto, Y., Nakaharu, Y., & Shimamoto, S. (2021) · Journal of International Medical Research · doi:10.1177/03000605211009721 · Cited by 14
Myers, S. M., & Challman, T. D. (2018) · American Academy of PediatricsItasca, IL eBooks · doi:10.1542/9781610021357-19 · Cited by 14
Martins, P. L. B., Torquato, G. C. P., Dias, G. A. P. F., Leite, I. B., GASPAR, T. M., Pinto, J. P., & Macêdo, D. S. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111089 · Cited by 14
Efficacy and Safety of Alpha-2 Agonists in Autism Spectrum Disorder: A Systematic Review
Kaye, A. D., Green, A. M., Claude, J. T., Daniel, C. P., Cooley, J. F., Sala, K. R., Potharaju, P., Rieger, R., Patil, S. S., Ahmadzadeh, S., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02980-0 · Cited by 13
Joshi, G., & Wilens, T. E. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.012 · Cited by 13
Using pharmacotherapy to address sleep disturbances in autism spectrum disorders
Mammarella, V., Orecchio, S., Cameli, N., Occhipinti, S., Marcucci, L., Meo, G. D., Innocenti, A., Ferri, R., & Bruni, O. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2267761 · Cited by 13
Identification and Functional Analysis of Long Non-coding RNAs in Autism Spectrum Disorders
Tong, Z., Zhou, Y., & Wang, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00849 · Cited by 13
Managing disruptive behaviour in autism-spectrum disorder with guanfacine
Propper, L. (2018) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.180039 · Cited by 12
Symptom scores and medication treatment patterns in children with ADHD versus autism.
Mayes, S., Waxmonsky, J., Baweja, R., Mattison, R., Memon, H., Klein, M., Hameed, U., & Waschbusch, D. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112937 · Cited by 13
Metadata
- Authors
- Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., Page, C., Ward, D., Deng, Y., Loo, S., Dziura, J., McDougle, C. J., & Research Units on Pediatric Psychopharmacology Autism Network
- Affiliations
- Seattle Children's Hospital (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2015-12-01
- Volume
- 172
- Issue
- 12
- Pages
- 1197-1206
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1933613998
- Cited by
- 201
- References
- 38
- Citations by year
- 2026: 12 · 2025: 21 · 2024: 24 · 2023: 18 · 2022: 21 · 2021: 22 · 2020: 25 · 2019: 15 · 2018: 14 · 2017: 11 · 2016: 16 · 2015: 2
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Yale University
- National Institutes of Health (UL1TR000454)
- National Institute of Mental Health (R01MH86927, R01MH086927, R01MH83739, R01MH083707, R01MH083739, R01MH083747)
- National Center for Research Resources (UL1RR024139)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Keywords
- guanfacine, autism spectrum disorder, hyperactivity, impulsivity, distractibility, ADHD medication, Aberrant Behavior Checklist, working memory, motor planning, blood pressure, adverse events, children
- MeSH terms
- Autism Spectrum Disorder, Adolescent, Child, Child, Preschool, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Hyperkinesis, Male, Memory, Short-Term, Neuropsychological Tests, Psychomotor Performance, Guanfacine, Treatment Outcome, Adrenergic alpha-2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.